Cidara: Janssen to Proceed Under License for Drug-Fc Conjugates Targeting Influenza

 Decision follows promising interim efficacy and safety data from ongoing Phase 1 and 2a trials

Cidara to receive a $7 million milestone payment and is eligible to receive an additional $685 million in milestones, plus royalties

https://www.biospace.com/article/releases/cidara-therapeutics-announces-janssen-s-election-to-proceed-under-its-license-agreement-relating-to-novel-drug-fc-conjugates-targeting-influenza/